Sleep1 source
Phase 3 Trial Finds AD109 Reduced Sleep Apnea Breathing Events by 44%
In a six-month randomized phase 3 trial involving 646 adults who could not tolerate or had declined CPAP, the once-nightly drug AD109 reduced apnea-hypopnea index scores by about 44%, compared with an 18% reduction with placebo. The treatment also improved several measures of nighttime oxygen disruption, but side effects led about 21% of participants to discontinue it.
Read report→